Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIXNASDAQ:BYSINASDAQ:EGRXNASDAQ:GNLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.55-3.5%$2.82$2.07▼$4.20$118.54M0.34102,038 shs194,671 shsBYSIBeyondSpring$3.11-8.5%$1.80$0.98▼$3.44$137.07M0.0729,274 shs213,609 shsEGRXEagle Pharmaceuticals$2.35$1.93$1.50▼$2.50$30.52M0.839,685 shs2 shsGNLXGenelux$2.92-3.3%$2.64$1.60▼$5.89$113.96M-0.49191,174 shs54,016 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-1.87%+5.44%+38.87%+17.20%+41.54%BYSIBeyondSpring+13.33%+35.46%+104.82%+109.88%+21.43%EGRXEagle Pharmaceuticals0.00%+11.90%+21.13%+88.00%-42.12%GNLXGenelux-6.50%+13.11%+21.77%-24.50%+26.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences3.2218 of 5 stars3.65.00.00.01.53.30.0BYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGNLXGenelux1.2551 of 5 stars3.60.00.00.02.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00153.52% UpsideBYSIBeyondSpring 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AGNLXGenelux 3.20Buy$17.75507.88% UpsideCurrent Analyst Ratings BreakdownLatest EGRX, GNLX, BYSI, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.004/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/26/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/21/2025ANIXAnixa BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K544.50N/AN/A$0.46 per share7.72BYSIBeyondSpring$1.75M71.65N/AN/A($0.37) per share-8.41EGRXEagle Pharmaceuticals$257.55M0.12$5.88 per share0.40N/A∞GNLXGenelux$10K11,020.08N/AN/A$0.76 per share3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/5/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AGNLXGenelux-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)Latest EGRX, GNLX, BYSI, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89BYSIBeyondSpringN/A2.492.49EGRXEagle PharmaceuticalsN/AN/AN/AGNLXGeneluxN/A4.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%BYSIBeyondSpring40.29%EGRXEagle Pharmaceuticals85.36%GNLXGenelux37.33%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%BYSIBeyondSpring29.31%EGRXEagle Pharmaceuticals28.90%GNLXGenelux9.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataGNLXGenelux1037.74 million34.23 millionNot OptionableEGRX, GNLX, BYSI, and ANIX HeadlinesRecent News About These CompaniesGenelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to "Hold" RatingJune 15 at 3:43 AM | americanbankingnews.comGenelux (NASDAQ:GNLX) Raised to "Hold" at Wall Street ZenJune 14, 2025 | marketbeat.comMillennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX)June 11, 2025 | marketbeat.comGenelux (NASDAQ:GNLX) Cut to Sell at Wall Street ZenJune 9, 2025 | americanbankingnews.comGenelux Co. (NASDAQ:GNLX) Given Average Recommendation of "Buy" by BrokeragesJune 7, 2025 | marketbeat.comGenelux (NASDAQ:GNLX) Downgraded by Wall Street Zen to SellJune 7, 2025 | marketbeat.comGenelux (NASDAQ:GNLX) Trading Up 3.3% - Time to Buy?June 6, 2025 | marketbeat.comGenelux Corporation (GNLX) Upgraded to Buy: Here's What You Should KnowJune 2, 2025 | zacks.comGenelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business UpdatesMay 6, 2025 | globenewswire.comWhy Genelux Corporation’s (GNLX) Stock Is Down 5.95%May 2, 2025 | aaii.comBenchmark Co. Remains a Buy on Genelux Corp. (GNLX)April 10, 2025 | markets.businessinsider.comGuggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)April 5, 2025 | markets.businessinsider.comGenelux reports FY24 EPS (95c), consensus (88c)March 29, 2025 | markets.businessinsider.comGenelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 28, 2025 | globenewswire.comDown -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a TurnaroundMarch 28, 2025 | zacks.comGenelux announces alignment with FDA of approval pathway for Olvi-VecMarch 26, 2025 | markets.businessinsider.comGenelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-VecMarch 26, 2025 | markets.businessinsider.comGenelux Corporation: Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung CancerMarch 25, 2025 | finanznachrichten.deGenelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung CancerMarch 25, 2025 | pipelinereview.comGenelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory DiseaseMarch 25, 2025 | markets.businessinsider.comWhy Genelux Corporation’s (GNLX) Stock Is Down 12.21%March 25, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, GNLX, BYSI, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.55 -0.13 (-3.53%) Closing price 04:00 PM EasternExtended Trading$3.61 +0.06 (+1.58%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.BeyondSpring NASDAQ:BYSI$3.11 -0.29 (-8.53%) Closing price 04:00 PM EasternExtended Trading$3.07 -0.04 (-1.29%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Eagle Pharmaceuticals NASDAQ:EGRX$2.35 0.00 (0.00%) As of 06/17/2025Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Genelux NASDAQ:GNLX$2.92 -0.10 (-3.31%) Closing price 04:00 PM EasternExtended Trading$2.90 -0.02 (-0.86%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
